Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

The Need For Adaptive Trial Design In Oncology Studies

Author : Kathleen Greenough

The changing nature of clinical trials means studies in all therapeutic areas are rising in complexity. But even with thousands of pharmaceutical trials currently underway across the globe, oncology trials are still presenting more difficulty to sponsors due to size and numerous changes in study protocols


Trial research needs to account for increased complexity and competition when recruiting patients in cancer studies. Patients and oncologists have more choices than ever for the placement of qualified study participants. Not only are treatments more specialised, but the industry is finally beginning to see positive results from decades of research. No longer do researchers have to rely solely on traditional approaches to existing cancer treatments, such as chemotherapy. Now, patients are being considered for immunotherapy and cell and gene therapy. According to the Alliance for Regenerative Medicine, at the outset of 2021 there were 1,220 active worldwide clinical trials in regenerative medicine and advanced cell and gene therapies, with a majority (554) of them aimed at oncology 2.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024